نتائج البحث - "Ryan Overland"

1

Supplementary Figures 1-4, Table 1 from Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

المؤلفون: Ulrik B. Nielsen, Birgit Schoeberl, Arthur J. Kudla, Michael J. Feldhaus, Matt Wallace, Neeraj Kohli, Jinming Gu, Stephanie Nguyen, Ryan Overland, Lia Luus, Bo Zhang, Shinji Oyama, Violette Paragas, Sharlene Adams, Brian D. Harms, Alexandra Huhalov, Charlotte F. McDonagh

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::740c3b57b3148fec19b2a1932a1c942b
https://doi.org/10.1158/1535-7163.22498605

View record in OpenAIRE

2

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

المؤلفون: Violette Paragas, Matt Wallace, Stephanie Nguyen, Ryan Overland, Michael Feldhaus, Neeraj Kohli, Lia Luus, Brian Harms, Birgit Schoeberl, Bo Zhang, Aruthur J Kudla, Sharlene Adams, Ulrik B. Nielsen, Charlotte Mcdonagh, Shinji Oyama, Jinming Gu, Alexandra Huhalov

المصدر: Molecular Cancer Therapeutics. 11:582-593

مصطلحات موضوعية: Cancer Research, Receptor, ErbB-3, Receptor, ErbB-2, medicine.drug_class, Neuregulin-1, Blotting, Western, Mice, Nude, Antineoplastic Agents, Mice, SCID, Pharmacology, Lapatinib, Monoclonal antibody, Inhibitory Concentration 50, Mice, Phosphatidylinositol 3-Kinases, Mice, Inbred NOD, Trastuzumab, Cell Line, Tumor, Neoplasms, Antibodies, Bispecific, medicine, Animals, Humans, Cyclin D1, ERBB3, skin and connective tissue diseases, Receptor, neoplasms, Cell Proliferation, biology, Chemistry, Kinase, Xenograft Model Antitumor Assays, Fusion protein, Oncology, Drug Design, Multiprotein Complexes, biology.protein, Female, Antibody, Protein Binding, Signal Transduction, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::648bfc7fca06202d74d2520d4e983bab
https://doi.org/10.1158/1535-7163.mct-11-0820

View record in OpenAIRE

3

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors

المؤلفون: Emily Pace, Matthew Onsum, Violette Paragas, Johanna Lahdenranta, Ulrik B. Nielsen, Charlotte Mcdonagh, Daniel C. Kirouac, Ryan Overland, Defne Yarar, Jin Y. Du

المصدر: Science signaling. 6(288)

مصطلحات موضوعية: MAPK/ERK pathway, Receptor, ErbB-3, MAP Kinase Signaling System, Receptor, ErbB-2, Neuregulin-1, Breast Neoplasms, Pharmacology, Lapatinib, Antibodies, Monoclonal, Humanized, Biochemistry, Models, Biological, Mice, Breast cancer, Trastuzumab, Antibodies, Bispecific, Antineoplastic Combined Chemotherapy Protocols, medicine, Biomarkers, Tumor, Animals, ERBB3, Computer Simulation, skin and connective tissue diseases, neoplasms, Molecular Biology, Protein kinase B, PI3K/AKT/mTOR pathway, Feedback, Physiological, business.industry, Cell Biology, medicine.disease, Oncogene Protein v-akt, Cancer research, Quinazolines, Female, Signal transduction, business, medicine.drug, Signal Transduction

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65e13e6d85a26b8a9beb896165e447d7
https://pubmed.ncbi.nlm.nih.gov/23943608

View record in OpenAIRE

4

Abstract A10: In silico design of biomarker-optimized drug combinations in ERBB2+ cancers

المؤلفون: Daniel C. Kirouac, Matthew Onsum, Ryan Overland, Charlotte Mcdonagh, Jinyan Du, Johanna Lahdenranta

المصدر: Cancer Research. 73:A10-A10

مصطلحات موضوعية: MAPK/ERK pathway, Cancer Research, MEK inhibitor, Pharmacology, Biology, Lapatinib, Oncology, Trastuzumab, Cancer research, medicine, ERBB3, Signal transduction, Protein kinase B, PI3K/AKT/mTOR pathway, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::288f5274ab2063b0a8d9a7ee7b0499a8
https://doi.org/10.1158/1538-7445.fbcr13-a10

View record in OpenAIRE

5

Abstract 4633: MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer

المؤلفون: Stephanie Nguyen, Violette Paragas, Daniel C. Kirouac, Johanna Lahdenranta, Bo Zhang, Matthew Onsum, Charlotte Mcdonagh, Ryan Overland, Ulrik B. Nielsen, Arthur J. Kudla, Jinyan Du

المصدر: Cancer Research. 73:4633-4633

مصطلحات موضوعية: MAPK/ERK pathway, Cancer Research, business.industry, Cell growth, Cancer Model, Cancer, Pharmacology, medicine.disease, chemistry.chemical_compound, Oncology, Paclitaxel, chemistry, Trastuzumab, medicine, Cancer research, Signal transduction, skin and connective tissue diseases, business, Protein kinase B, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::42dcf8cb90bd2cbfd0b8a5957f004378
https://doi.org/10.1158/1538-7445.am2013-4633

View record in OpenAIRE

6

Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer

المؤلفون: Violette Paragas, Matthew Onsum, Johanna Lahdenranta, Victor Moyo, Arthur J. Kudla, Charlotte Mcdonagh, Ulrik B. Nielsen, Ryan Overland

المصدر: Journal of Clinical Oncology. 31:48-48

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, biology, business.industry, Cancer, medicine.disease, Gastroesophageal Junction, Internal medicine, medicine, biology.protein, ERBB2 Positive, ERBB3, Antibody, skin and connective tissue diseases, Previously treated, business, neoplasms

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::0b127a59db224aab30eb9b4c0f643e12
https://doi.org/10.1200/jco.2013.31.4_suppl.48

View record in OpenAIRE

7

Abstract A8: Combating adaptive ERBB3-mediated resistance to ERBB2 inhibitors: In Silico optimization of MM-111 and lapatinib dosing regimens

المؤلفون: Mathew Onsum, Daniel C. Kirouac, Ulrik Nielson, Johanna Lahdenranta, Jinyan Du, Charlotte Mcdonagh, Ryan Overland

المصدر: Clinical Cancer Research. 18:A8-A8

مصطلحات موضوعية: MAPK/ERK pathway, Cancer Research, business.industry, Pharmacology, Lapatinib, Oncology, Mechanism of action, In vivo, Trastuzumab, medicine, ERBB3, medicine.symptom, skin and connective tissue diseases, business, Protein kinase B, PI3K/AKT/mTOR pathway, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::46aa9564d54fef9b917b672abd34cafd
https://doi.org/10.1158/1078-0432.mechres-a8

View record in OpenAIRE

8

Abstract 654: MM-111, an ErbB2/ErbB3 bispecific antibody, effectively combines with lapatinib to inhibit growth of ErbB2-overexpressing tumor cells

المؤلفون: Arthur J. Kudla, Shinji Oyama, Ryan Overland, Charlotte Mcdonagh, Clet Niyikiza, Violette Paragas, Gavin MacBeath, Lia Luus, Sharlene Adams, Ulrik B. Nielsen, Alexandra Huhalov

المصدر: Cancer Research. 71:654-654

مصطلحات موضوعية: Cancer Research, business.industry, Cancer, Estrogen receptor, Pharmacology, medicine.disease, Lapatinib, Oncology, Trastuzumab, medicine, Neuregulin, ERBB3, skin and connective tissue diseases, business, neoplasms, Protein kinase B, PI3K/AKT/mTOR pathway, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::906eca4afaa8809f483e7e3c1072b987
https://doi.org/10.1158/1538-7445.am2011-654

View record in OpenAIRE

9

Abstract 655: Combination of MM-111, an ErbB2/ErbB3 bispecific antibody, with endocrine therapies as an effective strategy for treatment of ER+/HER2+ breast cancer

المؤلفون: Gavin MacBeath, Olga Burenkova, Arthur J. Kudla, Clet Niyikiza, Stephanie Nguyen, Sharlene Adams, Ulrik B. Nielsen, Charlotte Mcdonagh, Bo Zhang, Ryan Overland, Alexandra Huhalov

المصدر: Cancer Research. 71:655-655

مصطلحات موضوعية: Cancer Research, Fulvestrant, business.industry, medicine.drug_class, Letrozole, Estrogen receptor, Pharmacology, medicine.disease, Breast cancer, Oncology, Estrogen, ErbB, Medicine, ERBB3, business, Tamoxifen, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::cbc60f8e77bab2e74d137847987ec17e
https://doi.org/10.1158/1538-7445.am2011-655

View record in OpenAIRE

10

Abstract 3485: MM-111, an ErbB2/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells driven by the ErbB2/ErbB3 oncogenic unit

المؤلفون: Alexandra Huhalov, Sharlene Adams, Ulrik B. Nielsen, Violette Paragas, Francis D. Gibbons, Lia Luus, Charlotte F. Mc Donagh, Arthur J. Kudla, Ryan Overland, Bo Zhang, Clet Niyikiza, Shinji Oyama, Stephanie Nguyen

المصدر: Cancer Research. 70:3485-3485

مصطلحات موضوعية: Cancer Research, business.industry, Cancer, Pharmacology, medicine.disease, Fusion protein, Breast cancer, Oncology, Trastuzumab, Cancer cell, medicine, ERBB3, skin and connective tissue diseases, Receptor, business, neoplasms, PI3K/AKT/mTOR pathway, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::c900866006726d52b2f69c3a68974f3a
https://doi.org/10.1158/1538-7445.am10-3485

View record in OpenAIRE

تنقيح النتائج